New fund to support translational research into paediatric inflammatory diseases

A new fund has been set up to drive bench-to-bedside research for children with inflammatory immune diseases. The Ped IMID fund (Fonds Pediatrische Immuun-inflammatoire Aandoeningen) was set up by Prof Carine Wouters (Pediatric Rheumatology), Prof Patrick Matthys (Immunobiology) and Prof Adrian Liston (Autoimmune Genetics) to build on our strong research cooperation. More than merely "translational research", where basic science is pushed into the clinic, our group performs "dialog research", where we meet regularly to discuss the clinic and the science of the most difficult-to-treat patients. We use the clinic to inform the research and the research to inform the clinic, and have already had multiple break-throughs in understanding and treating children with rare inflammatory diseases. 

If you would like to support our research, and allow us to take on more cases, you can transfer a tax-deductable donation to IBAN-number BE45 7340 1941 7789, BIC-code: KREDBEBB with the label "voor EBD-FOPIIA-O2010".

Another school class inspired...

... I just hope Annemarie and Dean warned them that science is a lifestyle choice, not a career.

You are never too young to become an immunologist

Many thanks for Annemarie van Nieuwenhuijze and Dean Franckaert for designing and implementing a school outreach program. 

New disease (and cure!) found

As part of an ERC funded research program, the Autoimmune Genetics Laboratory is searching the genomes of young children with severe immune diseases to look for novel genes (and hopefully treatments). In a collaboration with Prof Carine Wouters and Prof Isabelle Meyts at UZ Leuven, we found mutations in a new gene, CECR1, in three severely ill children. Two of the children were born with a severe immune deficiency, making them prone to infections, while the third developed an inflammatory disease known as Castleman's disease. Mutations in the same gene, which produces the protein ADA2, were independently found by two other groups to give vascular disease and early-onset stroke. 

These studies identify ADA2-deficiency as a previously undiagnosed primary immunodeficiency which includes components of immune deficiency, inflammation and vasculopathy. Most importantly, this new diagnosis comes with a successful cure: prior to genetic diagnosis, our clinical collaborators were able to successfully treat the disease with bone-marrow transplanation (for the immunodeficient patient) or tocilizumab (for the Castleman's disease patient). These results therefore not only add to our knowledge about medical genetics, but also provide a direct diagnosis-treatment pathway for any new children identified with these severe diseases.

Read more:

Van Eyck, Hershfield, Pombal, Kelly, Ganson, Moens, Frans, Schaballie, De Hertogh, Dooley, Bossuyt, Wouters, Liston* and Meyts*. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015 Jan;135(1):283-287.e5.

Van Eyck, Liston and Wouters. Mutant ADA2 in vasculopathies. N Engl J Med. 2014 Jul 31;371(5):480

Van Eyck, Liston and Meyts. Mutant ADA2 in vasculopathies. N Engl J Med.  2014 Jul 31;371(5):478-9.

If you would like to support our clinical research, and allow us to take on more cases like this one, you can make a tax-deductable donation the Ped IMID fund, by transferring to IBAN-number BE45 7340 1941 7789, BIC-code: KREDBEBB with the label "voor EBD-FOPIIA-O2010".

A new look at immune ageing

The thymus is the organ in which all T cells, a key white blood cell in our immune system, develop. The thymus shrinks with age, degenerating from a plump milky organ (just above the heart) to a ratty-looking fat-riddled vestige which barely produces any new T cells. This degeneration means that older persons are producing fewer and fewer T cells, contributing to the poor responses to vaccines and infections with age. Despite the importance of this process, there is a great debate in immunology over why the thymus gets worse with age, with some scientists pointing out the structural degeneration of the thymus itself, while others suggest that it is instead due to poorer function of the bone-marrow that sends stem cells to the thymus to be turned into T cells.

In a new study from the Autoimmune Genetics Laboratory, published in the European Journal of Immunology, we use a range of imaging and genetic techniques to address this key question. We undoubtly find the structural degeneration in the organ with age, but by comparing two mouse strains that have a thymus ageing at different rates, we find that the structural abnormalities do not actually limit production of T cells. Instead, it is the reduced function of the bone-marrow that leads to a reduction in new T cells. These results suggest that researchers looking into immune ageing direct their attention towards the bone-marrow, where rescuing stem cell production may allow even older persons to produce fresh T cells for a healthy life.

Data from Franckaert et al, European Journal of Immunology. The C57BL/6 mouse (top) has a thymus that ages slowly, while the FVB/N mouse (bottom) has a thymus that ages rapidly.

Scientific quote of the day

"To describe an organism, we do not try to specify each molecule in it, and catalogue it bit by bit, but rather to answer certain questions about it which reveal its pattern"

- Norbert Wiener, 1950 (quoted in Intolerant Bodies)

Pathway to a PhD

From my son's colouring-in book:

Relocate your lab to Belgium?

If you've ever thought of relocating your lab to Belgium, there is rarely a better deal than tenure plus up to €7.5 million in funding over five years. The Odysseus grants are opening!

PhD graduation

Congratulations to Dina Danso-Abeam who just graduated from her PhD in the laboratory!

Hints on scientific writing

My advice for writing a scientific article (for a top-tier journal).

Likewise, how to write a cover-letter.

If you get that far - how to interpret the editor's rejection (and you will be rejected) and then how to rebutt it.